Filing Flows › Viridian Therapeutics (VRDN) › Q3 2025
Viridian Therapeutics (VRDN) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Viridian Therapeutics (VRDN) reported revenue of $70.6M for the third quarter 2025 (Q3 2025), up 821-fold from a year earlier and up 941-fold from the quarter before. Operating margin was -56.7%, net loss $34.6M (49.0% of revenue).
Viridian Therapeutics, Q3 2025: revenue $70.6M (821× year over year), operating margin -56.7%, net loss $34.6M, operating cash flow −$84.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $70.6M | 941× | 821× |
| Operating profit | −$40.0M | — | — |
| Net earnings | −$34.6M | — | — |
| Operating cash flow | −$84.6M | — | — |
What changed
Revenue was $70.6M in Q3 2025, up 81958% year over year and up 93993% from the previous quarter. License was the largest line at 99% of revenue. Collaboration added $500K year over year (up 500%), 1% of the total change.
Operating costs exceeded revenue by $40.0M, an operating margin of -56.7%. Total costs grew 32% against revenue growth of 81958%. The fastest-growing cost line was General & admin (+69%). The quarter ended with a net loss of $34.6M, narrower than the previous quarter's $100.7M loss.
Operating cash flow was −$84.6M. Non-cash charges added back $110K of depreciation and amortization and $11.2M of share-based compensation. Working capital and other items used $61.4M. Capital expenditures of $127K exceeded it, leaving free cash flow of −$84.7M.
Questions
What was Viridian Therapeutics' revenue in the third quarter 2025?
Viridian Therapeutics (VRDN) reported revenue of $70.6M for the third quarter 2025 (Q3 2025), up 821-fold from a year earlier and up 941-fold from the quarter before.
Was Viridian Therapeutics profitable in the third quarter 2025?
Operating loss was $40.0M (-56.7% of revenue) and net loss $34.6M.